Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2006-12

AUTHORS

U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health

ABSTRACT

This guidance describes how the FDA evaluates patient-reported outcome (PRO) instruments used as effectiveness endpoints in clinical trials. It also describes our current thinking on how sponsors can develop and use study results measured by PRO instruments to support claims in approved product labeling (see appendix point 1). It does not address the use of PRO instruments for purposes beyond evaluation of claims made about a drug or medical product in its labeling. By explicitly addressing the review issues identified in this guidance, sponsors can increase the efficiency of their endpoint discussions with the FDA during the product development process, streamline the FDA's review of PRO endpoint adequacy, and provide optimal information about the patient's perspective of treatment benefit at the time of product approval. A PRO is a measurement of any aspect of a patient's health status that comes directly from the patient (i.e., without the interpretation of the patient's responses by a physician or anyone else). In clinical trials, a PRO instrument can be used to measure the impact of an intervention on one or more aspects of patients' health status, hereafter referred to as PRO concepts, ranging from the purely symptomatic (response of a headache) to more complex concepts (e.g., ability to carry out activities of daily living), to extremely complex concepts such as quality of life, which is widely understood to be a multidomain concept with physical, psychological, and social components. Data generated by a PRO instrument can provide evidence of a treatment benefit from the patient perspective. For this data to be meaningful, however, there should be evidence that the PRO instrument effectively measures the particular concept that is studied. Generally, findings measured by PRO instruments may be used to support claims in approved product labeling if the claims are derived from adequate and well-controlled investigations that use PRO instruments that reliably and validly measure the specific concepts at issue. The glossary defines many of the terms used in this guidance. In particular, the term instrument refers to the actual questions or items contained in a questionnaire or interview schedule along with all the additional information and documentation that supports the use of these items in producing a PRO measure (e.g., interviewer training and instructions, scoring and interpretation manual). The term conceptual framework refers to how items are grouped according to subconcepts or domains (e.g., the item walking without help may be grouped with another item, walking with difficulty, within the domain of ambulation, and ambulation may be further grouped into the concept of physical ability). FDA's guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead, guidance documents describe the Agency's current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in Agency guidance documents means that something is suggested or recommended but not required. First publication of the Draft Guidance by the Food and Drug Administration--February 2006. More... »

PAGES

79

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/1477-7525-4-79

DOI

http://dx.doi.org/10.1186/1477-7525-4-79

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1050813769

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/17034633


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Clinical Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Data Interpretation, Statistical", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Industry", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Guidelines as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pain Measurement", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Patient Satisfaction", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Product Labeling", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Psychometrics", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Quality of Life", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Surveys and Questionnaires", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "United States", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "United States Food and Drug Administration", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Montgomery County Department of Health and Human Services", 
          "id": "https://www.grid.ac/institutes/grid.414212.0", 
          "name": [
            "U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Food and Drug Administration, 5600 Fishers Lane, 2085, Rockville, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Montgomery County Department of Health and Human Services", 
          "id": "https://www.grid.ac/institutes/grid.414212.0", 
          "name": [
            "U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike, 20852-1448, Rockville, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "U.S. Department of Health and Human Services, Food and Drug Administration, Center for Devices and Radiological Health, Food and Drug Administration, 1350 Piccard Drive, 20850-430, Rockville, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health", 
        "type": "Person"
      }
    ], 
    "datePublished": "2006-12", 
    "datePublishedReg": "2006-12-01", 
    "description": "This guidance describes how the FDA evaluates patient-reported outcome (PRO) instruments used as effectiveness endpoints in clinical trials. It also describes our current thinking on how sponsors can develop and use study results measured by PRO instruments to support claims in approved product labeling (see appendix point 1). It does not address the use of PRO instruments for purposes beyond evaluation of claims made about a drug or medical product in its labeling. By explicitly addressing the review issues identified in this guidance, sponsors can increase the efficiency of their endpoint discussions with the FDA during the product development process, streamline the FDA's review of PRO endpoint adequacy, and provide optimal information about the patient's perspective of treatment benefit at the time of product approval. A PRO is a measurement of any aspect of a patient's health status that comes directly from the patient (i.e., without the interpretation of the patient's responses by a physician or anyone else). In clinical trials, a PRO instrument can be used to measure the impact of an intervention on one or more aspects of patients' health status, hereafter referred to as PRO concepts, ranging from the purely symptomatic (response of a headache) to more complex concepts (e.g., ability to carry out activities of daily living), to extremely complex concepts such as quality of life, which is widely understood to be a multidomain concept with physical, psychological, and social components. Data generated by a PRO instrument can provide evidence of a treatment benefit from the patient perspective. For this data to be meaningful, however, there should be evidence that the PRO instrument effectively measures the particular concept that is studied. Generally, findings measured by PRO instruments may be used to support claims in approved product labeling if the claims are derived from adequate and well-controlled investigations that use PRO instruments that reliably and validly measure the specific concepts at issue. The glossary defines many of the terms used in this guidance. In particular, the term instrument refers to the actual questions or items contained in a questionnaire or interview schedule along with all the additional information and documentation that supports the use of these items in producing a PRO measure (e.g., interviewer training and instructions, scoring and interpretation manual). The term conceptual framework refers to how items are grouped according to subconcepts or domains (e.g., the item walking without help may be grouped with another item, walking with difficulty, within the domain of ambulation, and ambulation may be further grouped into the concept of physical ability). FDA's guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead, guidance documents describe the Agency's current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in Agency guidance documents means that something is suggested or recommended but not required. First publication of the Draft Guidance by the Food and Drug Administration--February 2006.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/1477-7525-4-79", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1031326", 
        "issn": [
          "1477-7525"
        ], 
        "name": "Health and Quality of Life Outcomes", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "4"
      }
    ], 
    "name": "Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance", 
    "pagination": "79", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "f20e7b9f76632806fc808e60c7089143d866a7d8b4d41a8ccdfa40b804a67ace"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "17034633"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101153626"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/1477-7525-4-79"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1050813769"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/1477-7525-4-79", 
      "https://app.dimensions.ai/details/publication/pub.1050813769"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T19:58", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8681_00000516.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1186%2F1477-7525-4-79"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/1477-7525-4-79'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/1477-7525-4-79'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/1477-7525-4-79'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/1477-7525-4-79'


 

This table displays all metadata directly associated to this object as RDF triples.

135 TRIPLES      20 PREDICATES      43 URIs      35 LITERALS      23 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/1477-7525-4-79 schema:about N1a21e7d1f97b491b8f4c30e8dc563010
2 N1bb98bea90634ae1b4dfdaadd34e857d
3 N1cf8826ea2ae485a84cfb2ef450ec5bf
4 N5452e54867e04f229873775551fe2220
5 N753df97646b6497d9c28a9668681b426
6 N779e38ffe73f45e8b1fff3ff2219d38f
7 N804784e687484fa1a98a184490ad980b
8 N8dca35f6859f4230a377b544585f47f3
9 N9e7b064572844559a3e84ef49a84dff5
10 Na30496bd4ee84f188a9306483b85b4a3
11 Na7ce9ba15a9d477e8860a325761132f1
12 Naf9e8261117c4dbbb2b9afe95c6ea8cf
13 Nb4b9de3e2b044eb29b8070f1e097dd5d
14 Ne1cf714da48a4bc9b2cd3fbb983ee820
15 anzsrc-for:11
16 anzsrc-for:1117
17 schema:author N8ac6c693a9db4278b0d807bbf1240f26
18 schema:datePublished 2006-12
19 schema:datePublishedReg 2006-12-01
20 schema:description This guidance describes how the FDA evaluates patient-reported outcome (PRO) instruments used as effectiveness endpoints in clinical trials. It also describes our current thinking on how sponsors can develop and use study results measured by PRO instruments to support claims in approved product labeling (see appendix point 1). It does not address the use of PRO instruments for purposes beyond evaluation of claims made about a drug or medical product in its labeling. By explicitly addressing the review issues identified in this guidance, sponsors can increase the efficiency of their endpoint discussions with the FDA during the product development process, streamline the FDA's review of PRO endpoint adequacy, and provide optimal information about the patient's perspective of treatment benefit at the time of product approval. A PRO is a measurement of any aspect of a patient's health status that comes directly from the patient (i.e., without the interpretation of the patient's responses by a physician or anyone else). In clinical trials, a PRO instrument can be used to measure the impact of an intervention on one or more aspects of patients' health status, hereafter referred to as PRO concepts, ranging from the purely symptomatic (response of a headache) to more complex concepts (e.g., ability to carry out activities of daily living), to extremely complex concepts such as quality of life, which is widely understood to be a multidomain concept with physical, psychological, and social components. Data generated by a PRO instrument can provide evidence of a treatment benefit from the patient perspective. For this data to be meaningful, however, there should be evidence that the PRO instrument effectively measures the particular concept that is studied. Generally, findings measured by PRO instruments may be used to support claims in approved product labeling if the claims are derived from adequate and well-controlled investigations that use PRO instruments that reliably and validly measure the specific concepts at issue. The glossary defines many of the terms used in this guidance. In particular, the term instrument refers to the actual questions or items contained in a questionnaire or interview schedule along with all the additional information and documentation that supports the use of these items in producing a PRO measure (e.g., interviewer training and instructions, scoring and interpretation manual). The term conceptual framework refers to how items are grouped according to subconcepts or domains (e.g., the item walking without help may be grouped with another item, walking with difficulty, within the domain of ambulation, and ambulation may be further grouped into the concept of physical ability). FDA's guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead, guidance documents describe the Agency's current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in Agency guidance documents means that something is suggested or recommended but not required. First publication of the Draft Guidance by the Food and Drug Administration--February 2006.
21 schema:genre research_article
22 schema:inLanguage en
23 schema:isAccessibleForFree true
24 schema:isPartOf N5d514edd5f5c49eb876079fc171cf91f
25 Ne75dd3cc11fd4fdf8660130082e0596b
26 sg:journal.1031326
27 schema:name Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance
28 schema:pagination 79
29 schema:productId N50815170b1764c65859ab7832489f898
30 Nbe5ae78383694ffc8495b420affb659d
31 Nc5bdaa1437184c898bcfc77c323c96c4
32 Ne350836f67fc48fdbb919666cb35b357
33 Nff733d2a3538487a802af3053cead9a2
34 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050813769
35 https://doi.org/10.1186/1477-7525-4-79
36 schema:sdDatePublished 2019-04-10T19:58
37 schema:sdLicense https://scigraph.springernature.com/explorer/license/
38 schema:sdPublisher N28b42bbe6538483b98f7c35fb339dca0
39 schema:url http://link.springer.com/10.1186%2F1477-7525-4-79
40 sgo:license sg:explorer/license/
41 sgo:sdDataset articles
42 rdf:type schema:ScholarlyArticle
43 N1a21e7d1f97b491b8f4c30e8dc563010 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
44 schema:name Patient Satisfaction
45 rdf:type schema:DefinedTerm
46 N1bb98bea90634ae1b4dfdaadd34e857d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
47 schema:name Treatment Outcome
48 rdf:type schema:DefinedTerm
49 N1cf8826ea2ae485a84cfb2ef450ec5bf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
50 schema:name Drug Industry
51 rdf:type schema:DefinedTerm
52 N28b42bbe6538483b98f7c35fb339dca0 schema:name Springer Nature - SN SciGraph project
53 rdf:type schema:Organization
54 N2a919810682a45e38e883d3304f459cf schema:name U.S. Department of Health and Human Services, Food and Drug Administration, Center for Devices and Radiological Health, Food and Drug Administration, 1350 Piccard Drive, 20850-430, Rockville, MD, USA
55 rdf:type schema:Organization
56 N50815170b1764c65859ab7832489f898 schema:name dimensions_id
57 schema:value pub.1050813769
58 rdf:type schema:PropertyValue
59 N5452e54867e04f229873775551fe2220 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
60 schema:name Surveys and Questionnaires
61 rdf:type schema:DefinedTerm
62 N5d514edd5f5c49eb876079fc171cf91f schema:issueNumber 1
63 rdf:type schema:PublicationIssue
64 N753df97646b6497d9c28a9668681b426 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
65 schema:name Product Labeling
66 rdf:type schema:DefinedTerm
67 N779e38ffe73f45e8b1fff3ff2219d38f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
68 schema:name Clinical Trials as Topic
69 rdf:type schema:DefinedTerm
70 N804784e687484fa1a98a184490ad980b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
71 schema:name Quality of Life
72 rdf:type schema:DefinedTerm
73 N8ac6c693a9db4278b0d807bbf1240f26 rdf:first Nfb1b5d053e2d4d69b69cc9a290ce63b0
74 rdf:rest Nbb3ec5da99f2428e8bc8502a2d00fd33
75 N8b649b2d451d4f738083eecd11839cb8 schema:affiliation N2a919810682a45e38e883d3304f459cf
76 schema:familyName U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health
77 rdf:type schema:Person
78 N8dca35f6859f4230a377b544585f47f3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
79 schema:name United States
80 rdf:type schema:DefinedTerm
81 N8e75f0c974254a47be8749bc75b05f99 schema:affiliation https://www.grid.ac/institutes/grid.414212.0
82 schema:familyName U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research
83 rdf:type schema:Person
84 N9e7b064572844559a3e84ef49a84dff5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
85 schema:name United States Food and Drug Administration
86 rdf:type schema:DefinedTerm
87 Na30496bd4ee84f188a9306483b85b4a3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
88 schema:name Pain Measurement
89 rdf:type schema:DefinedTerm
90 Na7ce9ba15a9d477e8860a325761132f1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
91 schema:name Data Interpretation, Statistical
92 rdf:type schema:DefinedTerm
93 Naf9e8261117c4dbbb2b9afe95c6ea8cf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
94 schema:name Psychometrics
95 rdf:type schema:DefinedTerm
96 Nb4b9de3e2b044eb29b8070f1e097dd5d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
97 schema:name Humans
98 rdf:type schema:DefinedTerm
99 Nbb3ec5da99f2428e8bc8502a2d00fd33 rdf:first N8e75f0c974254a47be8749bc75b05f99
100 rdf:rest Ne2555cddddfe485f81fb6d251eebc9ea
101 Nbe5ae78383694ffc8495b420affb659d schema:name nlm_unique_id
102 schema:value 101153626
103 rdf:type schema:PropertyValue
104 Nc5bdaa1437184c898bcfc77c323c96c4 schema:name doi
105 schema:value 10.1186/1477-7525-4-79
106 rdf:type schema:PropertyValue
107 Ne1cf714da48a4bc9b2cd3fbb983ee820 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Guidelines as Topic
109 rdf:type schema:DefinedTerm
110 Ne2555cddddfe485f81fb6d251eebc9ea rdf:first N8b649b2d451d4f738083eecd11839cb8
111 rdf:rest rdf:nil
112 Ne350836f67fc48fdbb919666cb35b357 schema:name readcube_id
113 schema:value f20e7b9f76632806fc808e60c7089143d866a7d8b4d41a8ccdfa40b804a67ace
114 rdf:type schema:PropertyValue
115 Ne75dd3cc11fd4fdf8660130082e0596b schema:volumeNumber 4
116 rdf:type schema:PublicationVolume
117 Nfb1b5d053e2d4d69b69cc9a290ce63b0 schema:affiliation https://www.grid.ac/institutes/grid.414212.0
118 schema:familyName U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research
119 rdf:type schema:Person
120 Nff733d2a3538487a802af3053cead9a2 schema:name pubmed_id
121 schema:value 17034633
122 rdf:type schema:PropertyValue
123 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
124 schema:name Medical and Health Sciences
125 rdf:type schema:DefinedTerm
126 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
127 schema:name Public Health and Health Services
128 rdf:type schema:DefinedTerm
129 sg:journal.1031326 schema:issn 1477-7525
130 schema:name Health and Quality of Life Outcomes
131 rdf:type schema:Periodical
132 https://www.grid.ac/institutes/grid.414212.0 schema:alternateName Montgomery County Department of Health and Human Services
133 schema:name U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike, 20852-1448, Rockville, MD, USA
134 U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Food and Drug Administration, 5600 Fishers Lane, 2085, Rockville, MD, USA
135 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...